OncoMatch/Clinical Trials/NCT06349317
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Is NCT06349317 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib for hepatocellular carcinoma.
Treatment: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib — This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein tumor thrombus.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC ≥1.5×10^9/L; Platelets ≥80×10^9/L; Hemoglobin ≥90g/L
Kidney function
Serum creatinine ≤1.5×ULN, or if >1.5×ULN, creatinine clearance ≥45 mL/min; Urinalysis proteinuria <2+; if baseline proteinuria ≥2+, 24-hour urine protein <1g
Liver function
Total bilirubin ≤3× ULN; ALT and AST ≤5×ULN; Serum albumin ≥30g/L; Child-Pugh Class A
Cardiac function
QTc ≤450ms (males), ≤470ms (females); NYHA class II or above heart failure, LVEF <50%, unstable angina, MI within 1 year, significant arrhythmias excluded
Adequate organ and marrow function, as defined by the following laboratory values: ... Child-Pugh score of Class A; ... QTc > 450ms for males and >470ms for females ... heart failure of NYHA class II or above or echocardiography showing LVEF <50%; unstable angina; myocardial infarction within 1 year before treatment; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify